Candesartan cilexetil in children with hypertension or proteinuria: preliminary data

Simonetti, Giacomo D; von Vigier, Rodo O; Konrad, Martin; Rizzi, Mattia; Fossali, Emilio; Bianchetti, Mario G (2006). Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatric nephrology, 21(10), pp. 1480-2. Berlin: Springer 10.1007/s00467-006-0144-0

Full text not available from this repository. (Request a copy)

The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood. We were impressed by the neutral taste and the small size of the candesartan cilexetil tablets. This angiotensin II receptor blocker was used during 4 months in 17 pediatric patients (aged 0.5-16, median 4.5 years) with chronic arterial hypertension (n=6), overt proteinuria (n=2), or both (n=9). The initial candesartan dose of 0.23 (0.16-0.28) mg/kg body weight once daily (median and interquartile ranged) was doubled in ten patients [final dose 0.35 (0.22-0.47) mg/kg body weight]. No adverse clinical experiences were noted on candesartan. Candesartan increased plasma potassium by 0.3 (0.0-0.8) mmol/l (P<0.01). In children with arterial hypertension, blood pressure decreased by 9 (3-13)/9 (3-18) mmHg (P<0.01); in those with overt proteinuria the urinary albumin/creatinine ratio decreased by 279 (33-652) mg/mmol (P<0.05). In conclusion, in children candesartan reduces blood pressure and proteinuria with an excellent short-term tolerability profile.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine

UniBE Contributor:

von Vigier, Rodo; Konrad, Martin and Rizzi, Mattia










Factscience Import

Date Deposited:

04 Oct 2013 14:48

Last Modified:

17 Mar 2015 21:48

Publisher DOI:


PubMed ID:


Web of Science ID:


URI: (FactScience: 3081)

Actions (login required)

Edit item Edit item
Provide Feedback